We will include participants aged over 18 years and diagnosed with type 2 diabetes28; the HbA1c level of the participants will need to be over 7% (53.0 mmol/mol).9 Since pharmacokinetic parameters are slightly altered in the case of mild chronic kidney disease (CKD)29 after SGLT2 inhibitors are used, we will exclude trials that include participants with moderate to severe CKD. Here, SLC5A2 is linked to chronic kidney disease.